“Nonstatutory obviousness-type double patenting does not invalidate any PTE granted under 35 U.S.C. 156 if the claims are otherwise valid under its pre-PTE expiration date.” The Drug Price Competition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results